Sale disclosed
Johanna Friedl-Naderer
Chief Commercial Officer
Common Stock
- Reported value
- $21.92K
- Reported price
- $24.35 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Dyne Therapeutics, Inc.
Last 30 daysInsiders bought $40K · 1 buyer, led by Brian S. Posner (Director) with $40K. Sales: $247.78K by 3 insiders.
Showing the first 6 of 20 trades on this page.
Chief Commercial Officer
Common Stock
Chief Commercial Officer
Common Stock
Chief Medical Officer
Common Stock
Chief Medical Officer
Common Stock
CEO & President
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Chief Commercial Officer
Common Stock
Chief Medical Officer
Common Stock
CEO & President
Common Stock
Chief Financial Officer
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Chief Commercial Officer | Common StockSale10b5-1 | 900$24.35 / share | $21.92K | Sep 4Filed Sep 8 · 4d later | SEC filing |
| Chief Commercial Officer | Common StockSale10b5-1 | 185$18.88 / share | $3.49K | Sep 8Filed Sep 8 · 0d later | SEC filing |
| Chief Medical Officer | Common StockSale10b5-1 | 3,745$24.35 / share | $91.19K | Sep 4Filed Sep 8 · 4d later | SEC filing |
| Chief Medical Officer | Common StockSale10b5-1 | 1,290$18.88 / share | $24.36K | Sep 8Filed Sep 8 · 0d later | SEC filing |
| CEO & President | Common StockSale10b5-1 | 5,658$18.88 / share | $106.82K | Sep 8Filed Sep 8 · 0d later | SEC filing |
| Director | Common StockSale10b5-13 trades | 426,412avg $26.20 / share | $11.17M | Aug 13Filed Aug 17 · 4d later | 3 filings
|
| Director | Common StockSale10b5-13 trades | 2,160,516avg $25.00 / share | $54.01M | Aug 14Filed Aug 17 · 3d later | 3 filings
|
| Chief Commercial Officer | Common StockSale10b5-1 | 226$26.28 / share | $5.94K | Aug 13Filed Aug 17 · 4d later | SEC filing |
| Chief Medical Officer | Common StockSale10b5-1 | 1,556$26.28 / share | $40.89K | Aug 13Filed Aug 17 · 4d later | SEC filing |
| CEO & President | Common StockSale10b5-1 | 4,986$26.28 / share | $131.03K | Aug 13Filed Aug 17 · 4d later | SEC filing |
| Chief Financial Officer | Common StockSale10b5-1 | 1,797$26.28 / share | $47.23K | Aug 13Filed Aug 17 · 4d later | SEC filing |
| Director | Common StockSale10b5-12 trades | 261,460avg $25.51 / share | $6.67M | Jul 27Filed Jul 29 · 2d later | 2 filings
|
| Director | Common StockSale10b5-13 trades | 480,240avg $22.79 / share | $10.94M | Jul 6Filed Jul 8 · 2d later | 3 filings
|
Showing the latest 20 of 111 trades. Show all 111 trades
This reflects the filings imported so far, not a complete trading history.
$79,200 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.